AstraZeneca

Owlstone will give AstraZeneca access to its Breath Biopsy Services to identify breath-based biomarkers for stratifying and treating asthma and COPD patients.

Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.

Expanded Indications

The FDA has expanded the indications for both AstraZeneca's PARP inhibitor Lynparza and Myriad Genetics' BRACAnalysis CDx test, as GenomeWeb reports.

Myriad Genetics' BRACAnalysis CDx can identify which metastatic patients have BRCA mutations and would likely benefit from treatment with AstraZeneca's Lynparza.

Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.

By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.

The drugmaker will use Myriad's expanded molecular diagnostic panel to evaluate best responders to a combination of Lynparza and Avastin in clinical trials.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

The drugmaker is subsidizing the cost of BRCA testing for women diagnosed with ovarian cancers, for whom guidelines now recommend such testing for cancer therapy selection.

The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.

Pages

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.